Treatment with 5-FU modulated by low-dose CDDP for advanced cancers and recurrent cases of metastasis

Advanced gastric, colon and esophageal cancers (n = 21) were treated with 5-FU (250 mg) modulated by CDDP (5 mg). The reductive ratio of tumor was 6/21 (28.6%). Six cases of partial response (PR) were limited with no surgical treatment and exploratory laparotomy of all cases, and the effectiveness rate was 54.5% (6/11). Few side effects, such as dysfunction of bone marrow and kidney, were noted. Even if side effects occurred, they were mild. We concluded that excellent treatment with 5-FU modulated by CDDP has markedly improved the efficacy.